Nudging Providers to Curtail Dangerous Opioid Prescribing: A Trial to Investigate Mechanisms

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

12000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-15

Study Completion Date

2021-07-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Despite an enormous policy response, opioid prescribing remains well above historical levels and harms from opioids continue to mount. Nearly all states have Prescription Monitoring Programs (PMPs) to facilitate safer prescribing of opioids and other drugs, but research suggests these systems only deliver benefits when health care professionals are required to use them. Even with PMP mandates in place, providers may be unaware of the dangers of co-prescribing opioids with benzodiazepines or gabapentinoids, which include increased risk of overdose and death. Working with the Minnesota state government, the investigators will mail letters to guideline-discordant opioid prescribers that either highlight an upcoming legally mandated requirement to check the PMP before prescribing an opioid, inform and educate providers about patients filling concurrent prescriptions and the dangers of such co-prescribing, or both. Study participants will be randomized to receive no intervention or one of the three treatment letters. Using administrative data, the investigators will track effects of the letters on not only prescribing but also PMP usage and queries. Findings form the multiplicity of treatment messages and outcomes will shed light on the mechanisms driving overprescribing. Results will inform future work by state and local policymakers to make opioid prescribing safer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

E-mails to Nudge Safer and Better-Informed Prescribing of Risky Drugs

NCT06443385

Opioid Prescribing Prescription Drug Misuse

ACTIVE_NOT_RECRUITING NA

Postoperative Nudges to Reduce Opioid Prescribing

NCT05070338

Opioid Prescribing

COMPLETED NA

The Effect of Informative Letters on the Prescription and Receipt of Opioids

NCT03202745

Economics Fraud Delivery of Health Care +3 more

WITHDRAWN NA

Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care

NCT03537573

Acute Pain Headache Musculoskeletal Pain

COMPLETED NA

Study of Medication Compliance - a Comparison of Patients in Pain Management and Pre-surgical Patients

NCT01625065

Pain

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Opioid Use

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PMP Use Mandate

Group Type EXPERIMENTAL

PMP Use Mandate Letter

Intervention Type BEHAVIORAL

A letter with reminders about the mandate to check the PMP when prescribing opioids.

Prescribing Information

Group Type EXPERIMENTAL

Prescribing Information Letter

Intervention Type BEHAVIORAL

A letter with information about the prescriber's patients who received co-prescriptions. The letters will provide clinical background on the harms of co-prescribing and encourage prescribers to avoid co-prescribing in the future.

Prescribing Information + PMP Use Mandate

Group Type EXPERIMENTAL

Prescribing Information + PMP Use Mandate Letter

Intervention Type BEHAVIORAL

A letter combining the content of the PMP Use Mandate Letter and the Prescribing Information Letter. This letter will remind prescribers about the PMP use mandate and provide information about the prescriber's patients who received co-prescriptions.

Control / As-Usual

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PMP Use Mandate Letter

A letter with reminders about the mandate to check the PMP when prescribing opioids.

Intervention Type BEHAVIORAL

Prescribing Information Letter

A letter with information about the prescriber's patients who received co-prescriptions. The letters will provide clinical background on the harms of co-prescribing and encourage prescribers to avoid co-prescribing in the future.

Intervention Type BEHAVIORAL

Prescribing Information + PMP Use Mandate Letter

A letter combining the content of the PMP Use Mandate Letter and the Prescribing Information Letter. This letter will remind prescribers about the PMP use mandate and provide information about the prescriber's patients who received co-prescriptions.

Intervention Type BEHAVIORAL